Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints Life Science Investing
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD Life Science Investing
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET Life Science Investing
Medtronic Affera Mapping and Ablation System with Sphere-9 Catheter achieves endpoints for safety and efficacy, providing promising evidence for the future of atrial fibrillation treatment Life Science Investing
Late-breaking data show reliable performance of small-diameter defibrillation lead, the Medtronic OmniaSecure Life Science Investing
FDA APPROVES IMDELLTRA , THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER Life Science Investing
